Cargando…

Brachytherapy in a Single Dose of 10Gy as an “in situ” Vaccination

Radiotherapy (RT) is one of the major methods of cancer treatment. RT destroys cancer cells, but also affects the tumor microenvironment (TME). The delicate balance between immunomodulation processes in TME is dependent, among other things, on a specific radiation dose. Despite many studies, the opt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jarosz-Biej, Magdalena, Smolarczyk, Ryszard, Cichoń, Tomasz, Drzyzga, Alina, Czapla, Justyna, Urbaś, Zbigniew, Pilny, Ewelina, Matuszczak, Sybilla, Wojcieszek, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369911/ https://www.ncbi.nlm.nih.gov/pubmed/32605154 http://dx.doi.org/10.3390/ijms21134585

Ejemplares similares

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
por: Drzyzga, Alina, et al.
Publicado: (2021)

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
por: Czapla, Justyna, et al.
Publicado: (2023)

Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma
por: Kułach, Natalia, et al.
Publicado: (2021)

The Effect of Radiotherapy on Cell Survival and Inflammatory Cytokine and Chemokine Secretion in a Co-Culture Model of Head and Neck Squamous Cell Carcinoma and Normal Cells
por: Matuszczak, Sybilla, et al.
Publicado: (2023)

Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2015)

The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells
por: Czapla, Justyna, et al.
Publicado: (2019)

M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2018)

Characteristic of c-Kit(+) progenitor cells in explanted human hearts
por: Matuszczak, Sybilla, et al.
Publicado: (2014)

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2018)

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

D-K(6)L(9) Peptide Combination with IL-12 Inhibits the Recurrence of Tumors in Mice
por: Cichoń, Tomasz, et al.
Publicado: (2014)

Human Cardiac Mesenchymal Stromal Cells with CD105(+)CD34(-) Phenotype Enhance the Function of Post-Infarction Heart in Mice
por: Czapla, Justyna, et al.
Publicado: (2016)

Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2019)

Monitoring of diffusion properties and transverse relaxation time of mouse ischaemic muscle after administration of human mesenchymal stromal cells derived from adipose tissue
por: Skorupa, Agnieszka, et al.
Publicado: (2019)

Human ADSC xenograft through IL-6 secretion activates M2 macrophages responsible for the repair of damaged muscle tissue
por: Pilny, Ewelina, et al.
Publicado: (2019)

Polish Brachytherapy Society – Presidential opening: Chasing Brachytherapy
por: Wojcieszek, Piotr
Publicado: (2019)

Transcriptomes of human mesenchymal cells isolated from the right ventricle and epicardial fat differ strikingly both directly after isolation and long‐term culture
por: Stępniewski, Jacek, et al.
Publicado: (2019)

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease
por: Charvátová, Sandra, et al.
Publicado: (2023)

Antitumor Effects of Recombinant Antivascular Protein ABRaA-VEGF(121) Combined with IL-12 Gene Therapy
por: Ciomber, Agnieszka, et al.
Publicado: (2013)

Prostate cancer brachytherapy: guidelines overview
por: Wojcieszek, Piotr, et al.
Publicado: (2012)

7(th) Biannual Conference of the Polish Brachytherapy Society – presidential digest
por: Wojcieszek, Piotr
Publicado: (2020)

Basal Cell Carcinoma After High Dose Rate Brachytherapy: Medium-term Dermoscopic Evaluation of Cancer’s Response
por: Krzysztofiak, Tomasz, et al.
Publicado: (2023)

Basal Cell Carcinoma Treated with High Dose Rate (HDR) Brachytherapy—Early Evaluation of Clinical and Dermoscopic Patterns during Irradiation
por: Krzysztofiak, Tomasz, et al.
Publicado: (2021)

Acute and late toxicities in localized prostate cancer patients treated with low-dose (125)I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy)
por: Mukai, Yuki, et al.
Publicado: (2018)

Adjuvant vaginal brachytherapy as a part of management in early endometrial cancer
por: Kellas-Ślęczka, Sylwia, et al.
Publicado: (2012)

Prognostic Significance of STING Immunoexpression in Relation to HPV16 Infection in Patients with Squamous Cell Carcinomas of Oral Cavity and Oropharynx
por: Biesaga, Beata, et al.
Publicado: (2022)

Advanced dose calculation algorithm in superficial brachytherapy – the impact of tissue inhomogeneity on treatment plan dosimetry
por: Szlag, Marta, et al.
Publicado: (2021)

Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy
por: Hannoun-Levi, Jean-Michel, et al.
Publicado: (2012)

Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer
por: Akiyama, Hironori, et al.
Publicado: (2012)

Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
por: Motais, Benjamin, et al.
Publicado: (2021)

Pre-operative high-dose-rate brachytherapy in early-stage cervical cancer: long-term single-center results
por: Kellas-Ślęczka, Sylwia, et al.
Publicado: (2022)

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results
por: Latorre, Javier Anchuelo, et al.
Publicado: (2018)

Individual multi-catheter mould technique in high-dose-rate brachytherapy – personalized approach in treating multifocal angiosarcoma of the face
por: Szlag, Marta, et al.
Publicado: (2019)

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control
por: Mayrata, Esther, et al.
Publicado: (2021)

Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial Cancer
por: Arden, Jessica D., et al.
Publicado: (2021)

Interstitial high-dose-rate brachytherapy in locally advanced and recurrent vulvar cancer
por: Kellas-Ślęczka, Sylwia, et al.
Publicado: (2016)

To-Do and Not-To-Do in Model Studies of the Uptake, Fate and Metabolism of Metal-Containing Nanoparticles in Plants
por: Wojcieszek, Justyna, et al.
Publicado: (2020)

Predictive value of Excel forms based on an automatic calculation of dose equivalent in 2 Gy per fraction in adaptive brachytherapy for cervical cancer
por: Cheng, Guanghui, et al.
Publicado: (2020)

Adjuvant interstitial three-dimensional pulse-dose-rate-brachytherapy for lip squamous cell carcinoma after surgical resection
por: Chyrek, Artur Jan, et al.
Publicado: (2019)

Physical parameters in thermal imaging of basal cell cancer patients treated with high-dose-rate brachytherapy — first study
por: Kapek, Łukasz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1eel5a48h6b43ee1rtl2oe8oj4